Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background and objectives: In trials of people with type 2 diabetes, albuminuria reduction with renin-angiotensin system inhibitors is associated with lower risks of cardiovascular events and CKD progression. We tested whether progression or remission of microalbuminuria is associated with cardiovascular and renal risk in a well characterized cohort of type 1 diabetes. Design, setting, participants, & measurements: We studied 1441 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Albumin excretion rate (AER) was quantified annually or biennially for up to 30 years. For each participant, albuminuria status was defined over time as normoalbuminuria (AER continuously <30 mg/d), sustained microalbuminuria (AER, 30–299 mg/d on two consecutive visits), macroalbuminuria (AER≥300 mg/d), or remitted microalbuminuria (transition from sustained microalbuminuria to AER<30 mg/d on two consecutive visits). We tested associations of time-updated albuminuria status with adjudicated clinical cardiovascular events, the development of reduced GFR (<60 ml/min per 1.73 m 2 on two consecutive visits), and subclinical cardiovascular disease. Results: At least one cardiovascular event occurred in 184 participants, and 98 participants developed reduced eGFR. Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were each associated with higher risk of cardiovascular events (adjusted hazard ratios [HRs] and 95% confidence intervals [95% CIs]: 1.79 [1.13 to 2.85], 2.62 [1.68 to 4.07], and 2.65 [1.68 to 4.19], respectively) and reduced eGFR (adjusted HRs [95% CIs], 5.26 [2.43 to 11.41], 4.36 [1.80 to 10.57], and 54.35 [30.79 to 95.94], respectively). Compared with sustained microalbuminuria, remission to normoalbuminuria was not associated with reduced risk of cardiovascular events (adjusted HR, 1.33; 95% CI, 0.68 to 2.59) or reduced eGFR (adjusted HR, 1.75; 95% CI, 0.56 to 5.49). Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were associated with greater carotid intima-media thickness, and macroalbuminuria was associated with a greater degree of coronary artery calcification. Conclusions: In type 1 diabetes, microalbuminuria and macroalbuminuria are associated with higher risks of cardiovascular disease and reduced eGFR, but achieving a remission of established microalbuminuria to normoalbuminuria does not appear to improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have reported inconsistent results (43,44).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In randomized clinical trials, it has taken a number of years for bene fi ts of intensive glycemic control to manifest as improved clinical outcomes. 190,191,234,245,246,248,256”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [234]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in clinical trials, targeting lower HbA1c levels has reduced the rates of chronic diabetes complications in patients with T1D 190,232 -238 or T2D. 239 -246”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [234]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have overall reported cardiovascular and kidney outcome benefits (9,45,46).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In type 1 diabetes, remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have reported inconsistent results (43,44).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298 · cited 1×
“Current smoking 266 (18) 109 (26) 37 (22) 49 (27) Body mass index, kg/m(2) 23.”
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975 · cited 2×
“For example, in the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan study, all participants had macroalbuminuria at baseline, and RAS inhibitor–induced reductions in albuminuria were associated with lower subsequent CVD and renal risk (5,6).”
BackgroundRegression of Microalbuminuria in Type 1 Diabetes
Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. H., & Krolewski, A. S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021835 · Cited by 801
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750 · cited 1×
“For example, in the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan study, all participants had macroalbuminuria at baseline, and RAS inhibitor–induced reductions in albuminuria were associated with lower subsequent CVD and renal risk (5,6).”
BackgroundThe Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Self-citationTrajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 346
Diagnosis of diabetic kidney disease: state of the art and future perspective
Persson, F., & Rossing, P. (2018) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.003 · Cited by 335
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Donaghue, K. C., Marcovecchio, M. L., Wadwa, R. P., Chew, E. Y., Wong, T. Y., Calliari, L. E., Zabeen, B., Salem, M. A., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12742 · Cited by 298
“However, as highlighted by recent studies, even if albuminuria regresses into the normal range, patients’ experiences intermittent microalbuminuria have an increased cardiorenal risk.(12,43) Extensive evidence indicates that increases in albumin excretion,”
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
“However, this approach has not been formally evaluated in prospective trials, and in type 1 diabetes, remission of albuminuria may occur spontaneously and is not associated with improved clinical outcomes (10).”
BackgroundBjornstad, P., Dart, A. B., Donaghue, K. C., Dost, A., Feldman, E. L., Tan, G. S. W., Wadwa, R. P., Zabeen, B., & Marcovecchio, M. L. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13444 · Cited by 196
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Khan, M. S., Shahid, I., Anker, S. D., Fonarow, G. C., Fudim, M., Hall, M. E., Hernandez, A. F., Morris, A. A., Shafi, T., Weir, M. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.028 · Cited by 162
the Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 125
Vergès, B. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.001 · Cited by 112
Miller, R. G., Costacou, T., & Orchard, T. J. (2019) · Diabetes · doi:10.2337/db18-0515 · Cited by 110
Self-citationACE inhibitors and statins in adolescents with type 1 diabetes
Marcovecchio, M. L., Chiesa, S. T., Bond, S., Daneman, D., Dawson, S., Donaghue, K. C., Jones, T. W., Mahmud, F. H., Marshall, S. M., Neil, H. A. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703518 · Cited by 112
The Potential of Albuminuria as a Biomarker of Diabetic Complications
Raja, P., Maxwell, A. P., & Brazil, D. P. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07035-4 · Cited by 78
Sun, W., Yang, J., Wang, W., Hou, J., Cheng, Y., Fu, Y., Xu, Z., & Cai, L. (2017) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2017.12.005 · Cited by 69
Carbonell, M., Castelblanco, E., Valldeperas, X., Betriu, À., Traveset, A., Granado-Casas, M., Hernández, M., Vázquez, F., Martín, M., Rubinat, E., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0706-z · Cited by 68
Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110908 · Cited by 63
Lovshin, J. A., Bjornstad, P., Lovblom, L. E., Bai, J.-W., Lytvyn, Y., Boulet, G., Farooqi, M. A., Santiago, S., Orszag, A., Scarr, D., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1236 · Cited by 63
“Previous studies have found significant associations between CAC burden and DKD in a variety of diabetes populations (31) when DKD is defined according to the degree of albuminuria or by the degree of renal function decline (32,33).”
Self-citationPrognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 67
Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON
Jun, M., Ohkuma, T., Zoungas, S., Colagiuri, S., Mancia, G., Marre, M., Matthews, D., Poulter, N., Williams, B., Rodgers, A., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1467 · Cited by 57
Heerspink, H. J., Cherney, D. Z. I., Groop, P., Matthieu, C., Rossing, P. R., Tuttle, K. R., & McGill, J. B. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00168-7 · Cited by 53
Changes in albuminuria and subsequent risk of incident kidney disease
Sumida, K., Molnar, M. Z., Potukuchi, P. K., George, K., Thomas, F., Lu, J. L., Yamagata, K., Kalantar-Zadeh, K., & Kovesdy, C. P. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02720317 · Cited by 47
Yang, L.-L., Zhang, Q., Wu, Q., Yi, W., Yu, J., Mu, J., Zhang, J., Zeng, W., & Feng, B. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.04.044 · Cited by 45
Marcovecchio, M. L., Chiesa, S. T., Armitage, J., Daneman, D., Donaghue, K. C., Jones, T. W., Mahmud, F. H., Marshall, S. M., Neil, H. A. W., Dalton, R. N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1125 · Cited by 44
“Nevertheless, the links between early evidence of DN, including microalbuminuria, and CVD risk in type 1 diabetes remain robust (21,22).”
BackgroundResulton behalf of the FinnDiane Study Group, Sigfrids, F. J., Forsblom, C. M., Harjutsalo, V., Thorn, L. M., Wadén, J., Elonen, N., Ahola, A. J., Saraheimo, M., & Groop, P. (2018) · Diabetologia · doi:10.1007/s00125-018-4564-8 · Cited by 47
“Yet, in a recent paper from DCCT/EDIC [21], remission of albuminuria was not found to reduce the cardiovascular risk in individuals with type 1 diabetes.”
BackgroundInfluentialSeferović, J. P., Bentley–Lewis, R., Claggett, B. L., Díaz, R., Gerstein, H. C., Køber, L., Lawson, F. C., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1631263 · Cited by 45
“However, this effect was almost entirely eliminated by adjustment for updated mean HbA1c which led to the conclusion that glycemic exposure correlates very strongly with CVD and mortality, and that this is partly mediated by hyperglycemia-induced renal disease [15].”
BackgroundKidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
Garlo, K. G., White, W. B., Bakris, G. L., Zannad, F. M., Wilson, C., Kupfer, S., Vaduganathan, M., Morrow, D. A., Cannon, C. P., & Charytan, D. M. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05280517 · Cited by 40
The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes
Kahkoska, A. R., Isom, S. P., Divers, J., Mayer‐Davis, E. J., Dolan, L. M., SHAH, A. S., Afkarian, M., Pettitt, D. J., Lawrence, J. M., Marcovina, S. M., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.09.018 · Cited by 42
“Diabetic Medicine 2015;32(10):1354–1360.”
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Márquez, D. F., Ruiz‐Hurtado, G., Segura, J., & Ruilope, L. M. (2019) · F1000Research · doi:10.12688/f1000research.17212.1 · Cited by 41
A new strategy for vascular complications in young people with type 1 diabetes mellitus
on behalf of the Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT) study group, Marcovecchio, M. L., Dalton, R. N., Daneman, D., Deanfield, J. E., Jones, T. W., Neil, H. A. W., & Dunger, D. B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0198-2 · Cited by 34
Recent advances in diabetic kidney disease
Hanouneh, M. A., Echouffo-Tcheugui, J. B., & Jaar, B. G. (2021) · BMC Medicine · doi:10.1186/s12916-021-02050-0 · Cited by 33
Miller, R. G., Orchard, T. J., & Costacou, T. (2021) · Diabetes Care · doi:10.2337/dc21-1381 · Cited by 31
Self-citationAlbuminuria: Associated With Heart Failure Severity and Impaired Clinical Outcomes
Shuvy, M., Zwas, D. R., Lotan, C., Keren, A., & Gotsman, I. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.09.001 · Cited by 29
Pena, M. J., Stenvinkel, P., Kretzler, M., Adu, D., Agarwal, S. K., Coresh, J., Feldman, H. I., Fogo, A. B., Gansevoort, R. T., Harris, D. C. H., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.005 · Cited by 33
“Furthermore, compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and the development of macroalbuminuria are associated with a higher risk of CV events and reduced eGFR.(12) Moreover, it is important to determine whether higher levels of GFR (e.”
BackgroundIntensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus
Subramanian, S., & Hirsch, I. B. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.012 · Cited by 34
Cardiovascular complications of type 1 diabetes: update on the renal link
Orchard, T. J., & Costacou, T. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0949-7 · Cited by 29
Self-citationCostacou, T., Crandell, J., Kahkoska, A. R., Liese, A. D., Dabelea, D., Lawrence, J. M., Pettitt, D. J., Reynolds, K., Mayer‐Davis, E. J., & Mottl, A. K. (2018) · Diabetes Care · doi:10.2337/dc18-0319 · Cited by 26
“nificant effect on the risk for cardiovascular events (32) and all-cause, premature mortality (32,33).”
BackgroundBebu, I., Braffett, B. H., de Boer, I. H., Aiello, L. P., Bantle, J. P., Lorenzi, G. M., Herman, W. H., Gubitosi‐Klug, R., Perkins, B. A., Lachin, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1744 · Cited by 29
Self-citationMaleska, A. M., Hirtz, C., Casteleyn, E., Villard, O., Ducos, J., Avignon, A., Sultan, A., & Lehmann, S. (2017) · Bioanalysis · doi:10.4155/bio-2016-0278 · Cited by 27
ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Leong, A. Y., Ekinci, E. I., Nguyen, C. D., Milne, M., Hachem, M., Dobson, M., MacIsaac, R. J., & Jerums, G. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0767-3 · Cited by 25
“However, spontaneous remission of microalbuminuria to normoalbuminuria in a cohort study of T1D patients followed up for over 30 years was not associated with a reduction in CV or renal risk compared to sustained microalbuminuria despite adjustment for RASi inhibitors [13].”
BackgroundWretlind, A., Curovic, V. R., Suvitaival, T., Theilade, S., Tofte, N., Winther, S. A., Vilsbøll, T., Vestergaard, H., Rossing, P. R., & Legido‐Quigley, C. (2023) · Diabetes · doi:10.2337/db23-0052 · Cited by 23
Predictors for the development of microalbuminuria and interaction with renal function
Chatzikyrkou, C., Menne, J., Izzo, J. L., Viberti, G. C., Rabelink, T. J., Ruilope, L. M., Rump, C., Mertens, P. R., & Haller, H. G. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001491 · Cited by 27
“In patients with diabetes mellitus, progression from normoalbuminuria to microalbuminuria was associated with worsening structural glomerular lesions and regression of initial microalbuminuria to normoalbuminuria compared with sustained normoalbuminuria with higher risk of subsequent reductions in eGFR [31,32].”
BackgroundHarrison, T. G., Tam‐Tham, H., Hemmelgarn, B. R., Elliott, M. J., James, M. T., Ronksley, P. E., & Jun, M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.10.014 · Cited by 30
SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
Ahmed‐Sarwar, N., Nagel, A. K., Leistman, S., & Heacock, K. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017710481 · Cited by 23
EA15, MIR22, LINC00472 as diagnostic markers for diabetic kidney disease
Wang, Y., Zhu, D., Xie, X., Ding, M., Wang, Y., Sun, L., Zhang, N., Shen, E., & Wang, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27539 · Cited by 22
Ling, J., Ng, J. K., Lau, E. S. H., Ronald, C. W., Kong, A. P. S., Luk, A. O. Y., Kwok, J. S.-S., Szeto, C., Chan, J. C. N., & Chow, E. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.03.029 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Limonte, C. P., Gao, X., Bebu, I., Seegmiller, J. C., Karger, A. B., Lorenzi, G. M., Molitch, M. E., Karanchi, H., Perkins, B. A., de Boer, I. H., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2196 · Cited by 18
Self-citationGarofolo, M., Russo, E., Miccoli, R., Lucchesi, D., Giusti, L., Sancho‐Bornez, V., Daniele, G., Prato, S. D., & Penno, G. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.03.012 · Cited by 20
The distal nephron biomarkers associate with diabetic kidney disease progression
Tamargo, C. L., Coca, S. G., Thiessen‐Philbrook, H., Hu, D. G., Ix, J. H., Shlipak, M. G., Fried, L. F., Gutiérrez, O. M., Waikar, S. S., Schrauben, S. J., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.186836 · Cited by 13
“…DKD may have preserved eGFR early in their course despite extensive damage; levels of albuminuria are variable and may spontaneously regress, though even remitted albuminuria is associated with eGFR decline (6–8); and DKD can progress among persons with absent or low levels of albuminuria (9, 10).”
Lan, N. S. R., Bell, D. A., Watts, G. F., & Fegan, P. G. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000790 · Cited by 13
“Importantly, the presence of albuminuria, a marker of nephropathy, has been shown to be a significant predictor of adverse outcomes in individuals with T1D, with an associated two to four times greater risk of ASCVD complications and mortality [23,30].”
BackgroundSigfrids, F. J., Lithovius, R., Groop, P., & Thorn, L. M. (2024) · Diabetic Medicine · doi:10.1111/dme.15431 · Cited by 16
Moon, S., Tsay, J. J., Lampert, H. C., Dom, Z. I. M., Kostic, A. D., Smiles, A. M., & Niewczas, M. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87585-1 · Cited by 12
Viazzi, F. C., Ceriello, A., Fioretto, P., Giorda, C. B., Guida, P., Russo, G. T., Greco, E., Cosmo, S. D., & Pontremoli, R. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001749 · Cited by 13
Progression and regression of kidney disease in type 1 diabetes
Sigfrids, F. J., & Groop, P. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1282818 · Cited by 12
Wang, J., Li, J., Wang, A., Wang, J., Yang, Y., Chen, S., Wu, S., Zhao, M., Guo, X., & Zhang, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-12057-4 · Cited by 11
Tungsanga, S., Nantanawijit, R., Kiatamornrak, P., Kulvichit, W., Ngoensawat, U., Tachaboon, S., Dinhuzen, J., Chaisuriyong, W., Komolpis, K., Peerapornratana, S., et al. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-001412 · Cited by 11
Perkins, B. A., Bebu, I., Gao, X., Karger, A. B., Hirsch, I. B., Karanchi, H., Molitch, M. E., Zinman, B., Lachin, J. M., & de Boer, I. H. (2022) · Diabetes Care · doi:10.2337/dc21-1883 · Cited by 9
Self-citationRisk factors for nephropathy in persons with type 1 diabetes: a population-based study
Ahmadi, S. S., Pivodic, A., Svensson, A., Wedel, H., Rathsman, B., Nyström, T., Ludvigsson, J., & Lind, M. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01863-6 · Cited by 9
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Lal, R., & Shalitin, S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2510 · Cited by 10
“and Complications study indicate that even intermittent microalbuminuria may predict cardiovascular risk (23).”
Complicaciones microvasculares de la diabetes
Pérez‐Pevida, B., Llavero, M., Gargallo, J., & Escalada, J. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.003 · Cited by 17
Dixon, B. S. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09540916 · Cited by 10
Clinical Features and Natural Course of Diabetic Nephropathy
Rossing, P. R., & Frimodt‐Møller, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_2 · Cited by 12
Palomo‐Piñón, S., Aguilar-Alonso, J. A., Chavez-Iñiguez, J. S., Hernández-Arellanes, F. E., Mariano-Murga, J. A., Flores-Rodríguez, J. C., Pérez-López, M. J., Pérez, F. P., Treviño–Becerra, A., Guillén-Graf, A. E., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1376115 · Cited by 9
“However, other studies have shown that the remission to normo from micro-albuminuria was not associated with a reduction in the risk of renal and cardiovascular events (61).”
Complicaciones microvasculares de la diabetes
García-Ocaña, P., Cobos-Palacios, L., & Martínez, L. F. C. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.012 · Cited by 15
Risk of Microangiopathy in Patients with Epilepsy under Long-term Antiepileptic Drug Therapy
Chen, N.-C., Chen, C.-H., Lin, T., Chen, S., Tsai, M., Chang, C., Tsai, W., & Chuang, Y. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00113 · Cited by 8
Nomenclature of renal involvement in diabetes mellitus: unify to manage diversity
Marqués, M., Portolés, J. M., Fernández, C. M., Ortíz, A., & Navarro‐González, J. F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1533011 · Cited by 8
Khatri, M., Ryan, C. M., Gao, X., de Boer, I. H., Braffett, B. H., Molitch, M. E., Karger, A. B., Lorenzi, G. M., Lee, P., Trapani, V. R., et al. (2023) · Kidney360 · doi:10.34067/kid.0000000000000178 · Cited by 7
“2) Duration of diabetes, median (range), yr 4 (1–15) 24 (17–45) 37 (30–51) Proliferative diabetic retinopathy 0 153 (16%) 275 (26%) Cardiovascular disease 0 42 (4%) 158 (15%) Medication usage ACE inhibitors or ARB 0 390 (41%) 455 (43%) Lipid-lowering medication 0 378 (40%) 742 (71%) Laboratory results Total cholestero…”
Self-citationPark, Y. J., Yang, P., Yu, H. T., Kim, T., Jang, E., Uhm, J., Pak, H., Lee, M., Lip, G. Y. H., & Joung, B. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002987 · Cited by 7
Heerspink, H. J. L., Agarwal, R., Amor, A. J., Bech, J. N., Cherney, D. Z. I., Fiorina, P., Rossing, P. R., Schousboe, K., Selby, N. M., Anker, S. D., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf183 · Cited by 7
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Chai, S., Wu, S., Xin, S., Yuan, N., Sun, J., Zhang, X., & Ji, L. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001914 · Cited by 6
“It is clinically defined by the presence of impaired renal function and/or elevated urinary albumin excretion rate (UAER) and is the main cause of end-stage renal disease in both developed and developing countries.([6-8]) Microalbuminuria is the early clinical manifestation of diabetic nephropathy and is the main basi…”
BackgroundChronic kidney disease in patients with long-term type 1 diabetes mellitus
Yevloyeva, M. I., Arutyunova, M., Severina, A. S., Trubitsyna, N. P., Zaytseva, N. V., Shamhalova, M., & Shestakova, M. V. (2023) · Diabetes Mellitus · doi:10.14341/dm13108 · Cited by 5
Zheng, X., Yang, F., Chen, X., Yang, Y., Zhu, X., Chen, C., & Yang, J. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3432 · Cited by 6
Type 1 Diabetes and Cardiovascular Health
Pesantez, M., Ebekozien, O. A., & Vendrame, F. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.07.003 · Cited by 5
Keum, Y., Caramori, M. L., Cherney, D. Z. I., Crandall, J. P., de Boer, I. H., Lingvay, I., McGill, J. B., Polsky, S., Pop‐Busui, R., Rossing, P. R., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000567 · Cited by 4
“29 Thus, if a trial is designed to include individuals with moderately increased albuminuria, the data from this study suggest that inclusion could be based on historic UAER/UACR values regardless of the baseline urinary albumin level.”
Yarhere, I. E., Jaja, T., & Anolue, M. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.161.23782 · Cited by 4
[Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review].
Fang, C., Sun, L., Liu, Y., Xiao, L., & Sun, L. (2023) · 四川大学学报:医学版 · doi:10.12182/20231160102 · Cited by 3
He, W. W., Zhu, W., Liu, Y., Ye, M., Wang, H., Li, X., Lin, H., Liu, D., & Yao, F. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0665-7 · Cited by 2
Park, S. K., Jung, J. Y., Kim, M. H., Oh, C., Ha, E., Yang, E. H., Lee, H. C., Shin, S., Hwang, W. Y., Lee, S.-H., et al. (2023) · Epidemiology and Health · doi:10.4178/epih.e2023088 · Cited by 3
“Post hoc analyses in patients with diabetes showed that remission of albuminuria assessed by UACR was not associated with a lower risk of CVD [30,31].”
BackgroundMosa, O. F., Mahmoud, R., & Said, A. (2018) · SANAMED · doi:10.24125/sanamed.v13i2.254 · Cited by 2
Assessment of copeptin levels in children with type 1 diabetes
Fathalla, M. M. F., Kamal, H. M., & GabAllah, A. M. (2019) · Zagazig University Medical Journal · doi:10.21608/zumj.2019.14517.1322 · Cited by 4
Subclinical macroangiopathic target organ damage in type 1 diabetes mellitus patients
Błaszkowska, M., Shalimova, A., Wolnik, B., Orłowska-Kunikowska, E., Graff, B., Hoffmann, M., Nilsson, P. M., Wolf, J., & Narkiewicz, K. (2020) · Blood Pressure · doi:10.1080/08037051.2020.1770054 · Cited by 3
Ahmadizar, F., & der Zee, A. H. M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.25 · Cited by 2
McNally, E. H., Goodman, I. R., Morris, R., MALIEKKAL, J., Saeed, D., Tan, H. W., Berry, S. A., Elliott, J., & Iqbal, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71129 · Cited by 1
“In addition to incorporating data on diabetic eye disease, future studies should also examine the cardiometabolic effects of Omnipod 5, including changes in blood pressure, lipid profiles and urinary ACR, an important predictor of long-term cardiometabolic risk [34, 35].”
Zhang, J., Zhong, Q., Lin, Y., Zhang, Y., Teng, Y., Chen, J., Ou, C., & Feng, W. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117574 · Cited by 1
Macrovascular Disease in Type 1 Diabetes
Petrie, J. R. (2022) · doi:10.1093/med/9780198870197.003.0281 · Cited by 2
Yoldaş, T., Örün, U. A., Sağsak, E., Aycan, Z., Kaya, Ö., Özgür, S., & Karademir, S. (2018) · Echocardiography · doi:10.1111/echo.13889 · Cited by 1
Diabetes and the cardiovascular system
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch6
Fall 16: Spätschäden – 70 Jahre, ♀, DM Typ 1, Albuminurie und Blutdruckspitzen
Kihm, L. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_16
Conte, C., & Secchi, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00023-x
Metadata
- Authors
- de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., Zinman, B., & for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington;
- George Washington University (US)
- Northwestern University (US)
- University of Pittsburgh (US)
- Hospital for Sick Children (CA)
- University Health Network (CA)
- University of Minnesota (US)
- Mount Sinai Hospital (CA)
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-10-24
- Volume
- 11
- Issue
- 11
- Pages
- 1969-1977
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5108190
- OpenAlex
- W2537149664
- Semantic Scholar
- 24c112fdab228e526acf749547e57594378cc73a
- Cited by
- 114
- References
- 26
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 11 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 23 · 2017: 14 · 2016: 4
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01dk094157-13)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, R01DK088762, P30DK017047)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- albuminuria, microalbuminuria, type 1 diabetes, urinary albumin excretion rate, cardiovascular events, reduced eGFR, chronic kidney disease progression, macroalbuminuria, subclinical cardiovascular disease, DCCT/EDIC, renin-angiotensin system inhibitors, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy
- MeSH terms
- Adult, Albuminuria, Angina Pectoris, Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Male, Middle Aged, Myocardial Infarction, Randomized Controlled Trials as Topic, Stroke, Renal Insufficiency, Chronic, Young Adult, Carotid Intima-Media Thickness, Vascular Calcification, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.